BOULDER, Colo.–(BUSINESS WIRE)—- $BDSX #patientsfirst–Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for first quarter ended March 31, 2023 after the close of trading on Thursday, May 11. Biodesix’s management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webca
Click here to view original post
News
Weekly Policy Blog: PDAB Selects Drugs for Affordability Reviews
On Friday, August 4, the Colorado Prescription Drug Affordability Board (PDAB) selected five drugs for affordability reviews: Enbrel, Genvoya, Cosentyx, Stelara, and Trikafta. PDAB staff plan to begin conducting affordability reviews for the first three […]
News
Why Are These Athletes Collapsing? A Cardiologist Responds
Athletes normally grab headlines with their on-field play, but in recent months several athletes have made news of a sobering kind: They’ve suddenly collapsed during a game or practice. Click here to view original post […]
News
iCRYO Continues to Expand Across North America, Introducing First Location Within 24 Hour Fitness in Aurora, Colorado Opening October 2022
The Premium Health Care Franchise Expands to Colorado as Global Demand for Cryotherapy & Recovery Services Grows HOUSTON, Sept. 29, 2022 /PRNewswire/ — iCRYO, the fast-growing recovery and wellness brand, is pleased to announce and […]
